Hudson Bay Capital Management LP 89bio, Inc. Transaction History

Hudson Bay Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $1.8 Million - $2.91 Million	171,835 New	171,835 $2.62 Million
Q2 2022 Aug 12, 2022	BUY	$2.09 - $4.02 $161,193 - $310,046	77,126 New	77,126 $248,000
Q1 2021 May 14, 2021	SELL	$20.22 - $26.73 $1.01 Million - $1.34 Million	-50,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$23.16 - $28.08 $57,900 - $70,200	-2,500 Reduced 4.76%	50,000 $1.22 Million
Q3 2020 Nov 12, 2020	BUY	$24.34 - $38.82 $1.28 Million - $2.04 Million	52,500 New	52,500 $1.35 Million

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.